Organogenesis Holdings Net Income Over Time
| ORGO Stock | USD 3.84 0.01 0.26% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Organogenesis Holdings Performance and Organogenesis Holdings Correlation. Organogenesis | Build AI portfolio with Organogenesis Stock |
Will Biotechnology sector continue expanding? Could Organogenesis diversify its offerings? Factors like these will boost the valuation of Organogenesis Holdings. Anticipated expansion of Organogenesis directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Organogenesis Holdings data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 0.222 | Earnings Share (0.08) | Revenue Per Share | Quarterly Revenue Growth 0.31 | Return On Assets |
Investors evaluate Organogenesis Holdings using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Organogenesis Holdings' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Organogenesis Holdings' market price to deviate significantly from intrinsic value.
It's important to distinguish between Organogenesis Holdings' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Organogenesis Holdings should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Organogenesis Holdings' market price signifies the transaction level at which participants voluntarily complete trades.
Cross Equities Net Income Analysis
Compare Organogenesis Holdings and related stocks such as SNDL Inc, Monopar Therapeutics, and Emergent Biosolutions Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SNDL | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (13 M) | (3 M) | (271.5 M) | (233.2 M) | (227 M) | (335.1 M) | (172.7 M) | (94.8 M) | (85.3 M) | (89.6 M) |
| MNPR | (687 K) | (687 K) | (687 K) | (687 K) | (687 K) | (687 K) | (1.2 M) | (16.6 M) | (3.2 M) | (4.1 M) | (6.3 M) | (9.1 M) | (10.5 M) | (8.4 M) | (15.6 M) | (14 M) | (13.3 M) |
| EBS | (554 K) | 23 M | 23.5 M | 31.1 M | 36.7 M | 62.9 M | 51.8 M | 82.6 M | 62.7 M | 54.5 M | 305.8 M | 219.5 M | (223.8 M) | (760.5 M) | (190.6 M) | (171.5 M) | (163 M) |
| ESPR | (10.7 M) | (10.8 M) | (11.7 M) | (26.1 M) | (36.4 M) | (49.8 M) | (75 M) | (167 M) | (201.8 M) | (97.2 M) | (143.6 M) | (269.1 M) | (233.7 M) | (209.2 M) | (51.7 M) | (46.6 M) | (48.9 M) |
| EOLS | (31.1 M) | (31.1 M) | (31.1 M) | (31.1 M) | (31.1 M) | (31.1 M) | (20.1 M) | (4.5 M) | (46.9 M) | (90 M) | (163 M) | (46.8 M) | (74.4 M) | (61.7 M) | (50.4 M) | (45.4 M) | (47.6 M) |
| SIGA | (2.3 M) | 13.6 M | (14.5 M) | (17.2 M) | (265.5 M) | (39.5 M) | (39.7 M) | (36.2 M) | 421.8 M | (7.2 M) | 56.3 M | 69.5 M | 33.9 M | 68.1 M | 59.2 M | 68.1 M | 71.5 M |
| ANGO | 343 K | (5.2 M) | (1.2 M) | 2.3 M | (3.4 M) | (43.6 M) | (7.1 M) | 16.3 M | 61.3 M | (166.8 M) | (31.5 M) | (26.5 M) | (52.4 M) | (184.3 M) | (34 M) | (30.6 M) | (29.1 M) |
| BCYC | (13.5 M) | (13.5 M) | (13.5 M) | (13.5 M) | (13.5 M) | (13.5 M) | (13.5 M) | (16.3 M) | (21.8 M) | (30.6 M) | (51 M) | (66.8 M) | (112.7 M) | (180.7 M) | (169 M) | (152.1 M) | (144.5 M) |
| VREX | 109.6 M | 109.6 M | 109.6 M | 110.1 M | 80 M | 68.5 M | 51.6 M | 27.5 M | 15.5 M | (57.9 M) | 17.4 M | 30.3 M | 48.2 M | (47.7 M) | (69.9 M) | (62.9 M) | (59.8 M) |
| CMPX | (38.3 M) | (38.3 M) | (38.3 M) | (38.3 M) | (38.3 M) | (38.3 M) | (38.3 M) | (38.3 M) | (38.3 M) | (34.7 M) | (29.5 M) | (82.2 M) | (39.2 M) | (42.5 M) | (49.4 M) | (44.4 M) | (46.7 M) |
Organogenesis Holdings and related stocks such as SNDL Inc, Monopar Therapeutics, and Emergent Biosolutions Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Organogenesis Holdings financial statement analysis. It represents the amount of money remaining after all of Organogenesis Holdings operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Organogenesis Holdings | ORGO |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 85 Dan Road, |
| Exchange | NASDAQ Exchange |
USD 3.84
Check out Organogenesis Holdings Performance and Organogenesis Holdings Correlation. To learn how to invest in Organogenesis Stock, please use our How to Invest in Organogenesis Holdings guide.You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Organogenesis Holdings technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.